JP7083760B2 - 卵巣癌の治療方法 - Google Patents

卵巣癌の治療方法 Download PDF

Info

Publication number
JP7083760B2
JP7083760B2 JP2018568951A JP2018568951A JP7083760B2 JP 7083760 B2 JP7083760 B2 JP 7083760B2 JP 2018568951 A JP2018568951 A JP 2018568951A JP 2018568951 A JP2018568951 A JP 2018568951A JP 7083760 B2 JP7083760 B2 JP 7083760B2
Authority
JP
Japan
Prior art keywords
cancer
niraparib
patient
patients
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018568951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524690A (ja
JP2019524690A5 (enExample
Inventor
メアリー リン ヘドリー，
ロバート マーテル，
Original Assignee
テサロ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7083760(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by テサロ， インコーポレイテッド filed Critical テサロ， インコーポレイテッド
Publication of JP2019524690A publication Critical patent/JP2019524690A/ja
Publication of JP2019524690A5 publication Critical patent/JP2019524690A5/ja
Priority to JP2021212103A priority Critical patent/JP2022031478A/ja
Application granted granted Critical
Publication of JP7083760B2 publication Critical patent/JP7083760B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018568951A 2016-06-29 2017-06-29 卵巣癌の治療方法 Active JP7083760B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021212103A JP2022031478A (ja) 2016-06-29 2021-12-27 卵巣癌の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662356461P 2016-06-29 2016-06-29
US62/356,461 2016-06-29
US201662402427P 2016-09-30 2016-09-30
US62/402,427 2016-09-30
US201762470141P 2017-03-10 2017-03-10
US62/470,141 2017-03-10
PCT/US2017/040039 WO2018005818A1 (en) 2016-06-29 2017-06-29 Methods of treating ovarian cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021212103A Division JP2022031478A (ja) 2016-06-29 2021-12-27 卵巣癌の治療方法

Publications (3)

Publication Number Publication Date
JP2019524690A JP2019524690A (ja) 2019-09-05
JP2019524690A5 JP2019524690A5 (enExample) 2020-08-13
JP7083760B2 true JP7083760B2 (ja) 2022-06-13

Family

ID=60787744

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018568951A Active JP7083760B2 (ja) 2016-06-29 2017-06-29 卵巣癌の治療方法
JP2021212103A Pending JP2022031478A (ja) 2016-06-29 2021-12-27 卵巣癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021212103A Pending JP2022031478A (ja) 2016-06-29 2021-12-27 卵巣癌の治療方法

Country Status (24)

Country Link
US (5) US12383542B2 (enExample)
EP (2) EP3478286B1 (enExample)
JP (2) JP7083760B2 (enExample)
KR (2) KR102510996B1 (enExample)
CN (1) CN109640992A (enExample)
AU (1) AU2017290244B2 (enExample)
BR (1) BR112018077492A2 (enExample)
CA (1) CA3029671C (enExample)
DK (1) DK3478286T3 (enExample)
ES (1) ES2969816T3 (enExample)
FI (1) FI3478286T3 (enExample)
HR (1) HRP20240136T1 (enExample)
HU (1) HUE064978T2 (enExample)
IL (1) IL263925B2 (enExample)
LT (1) LT3478286T (enExample)
MX (1) MX394062B (enExample)
NZ (1) NZ749413A (enExample)
PL (1) PL3478286T3 (enExample)
PT (1) PT3478286T (enExample)
RS (1) RS65180B1 (enExample)
SG (1) SG11201811564QA (enExample)
SI (1) SI3478286T1 (enExample)
SM (1) SMT202400105T1 (enExample)
WO (1) WO2018005818A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478286B1 (en) 2016-06-29 2024-01-03 Tesaro, Inc. Methods of treating ovarian cancer
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
EP3689419A1 (en) 2016-11-01 2020-08-05 AnaptysBio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
TWI879716B (zh) * 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
KR20200118117A (ko) * 2018-02-05 2020-10-14 테사로, 인코포레이티드 소아용 니라파립 제제 및 소아용 치료 방법
WO2019195443A1 (en) * 2018-04-04 2019-10-10 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor
EP3860988A1 (en) 2018-10-03 2021-08-11 Tesaro, Inc. Crystalline forms of niraparib freebase
ES2967517T3 (es) 2018-10-03 2024-04-30 Tesaro Inc Sales de niraparib
US10395772B1 (en) 2018-10-17 2019-08-27 Tempus Labs Mobile supplementation, extraction, and analysis of health records
EP3857555A4 (en) 2018-10-17 2022-12-21 Tempus Labs DATA-BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND PROCEDURES
CA3122070A1 (en) 2018-12-03 2020-06-11 Tempus Labs, Inc. Clinical concept identification, extraction, and prediction system and related methods
JP2022516170A (ja) * 2019-01-04 2022-02-24 アクティニウム ファーマシューティカルズ インコーポレイテッド Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
TW202116316A (zh) * 2019-07-15 2021-05-01 美商提薩羅有限公司 治療卵巢、輸卵管及腹膜癌之方法
AU2020332939B2 (en) * 2019-08-22 2025-12-11 Tempus Ai, Inc. Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data
EP4085053A4 (en) * 2019-12-31 2023-12-27 Kinnate Biopharma Inc. TREATING CANCER WITH CDK12/13 INHIBITORS
EP4090380A1 (en) * 2020-01-13 2022-11-23 Gradalis, Inc. Methods for treating cancers using gm-csf encoding polynucleotide and additional agents
CN116490776A (zh) * 2020-10-29 2023-07-25 德州大学系统董事会 用于检测和治疗卵巢癌的方法
KR102858757B1 (ko) 2022-01-25 2025-09-10 서울대학교산학협력단 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법
CN119156216A (zh) 2022-02-15 2024-12-17 特沙诺有限公司 尼拉帕尼用于治疗脑癌的用途
CN115253066A (zh) * 2022-07-21 2022-11-01 湖南安泰康成生物科技有限公司 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置
CN116092631A (zh) * 2023-01-17 2023-05-09 湖南安泰康成生物科技有限公司 铁死亡诱导剂与电场联用的肿瘤治疗系统
WO2025061057A1 (en) * 2023-09-19 2025-03-27 Impact Therapeutics (Shanghai) , Inc Use of a parp inhibitor in maintenance therapy of ovarian cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108986A1 (en) 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4611441B2 (ja) 2006-04-03 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール及びベンゾトリアゾール誘導体
GEP20115337B (en) 2007-01-10 2011-11-25 St Di Ricerche Di Biologia Molecolare P Angeletti Spa Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
KR101598231B1 (ko) 2007-10-17 2016-02-26 쿠도스 파마슈티칼스 리미티드 4-[3-(4-시클로프로판카르보닐-피페라진-1-카르보닐)-4-플루오로-벤질]-2ｈ-프탈라진-1-온
NZ586123A (en) * 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors
US8500933B2 (en) 2007-12-14 2013-08-06 Guardian Industries Corp. Localized heating of edge seals for a vacuum insulating glass unit, and/or unitized oven for accomplishing the same
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
JP5468015B2 (ja) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
EA020756B1 (ru) 2009-08-26 2015-01-30 Сефалон, Инк. Новые формы полициклического соединения
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2011153383A1 (en) 2010-06-04 2011-12-08 Bipar Science, Inc. Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
WO2011160063A2 (en) 2010-06-18 2011-12-22 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
CA2779052A1 (en) 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014052550A1 (en) * 2012-09-27 2014-04-03 Thomas Jefferson University Use of parp inhibitors to treat breast cancer
US20150313922A1 (en) 2012-11-28 2015-11-05 Sloan-Kettering Institute For Cancer Research Compositions and methods for the treatment of cancers associated with a deficiency in the mre11/rad50/nbs1 dna damage repair complex
EP3406594A1 (en) 2012-12-07 2018-11-28 Merck Sharp & Dohme Corp. Biocatalytic transamination process
EP2928473B1 (en) 2012-12-07 2017-06-28 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
WO2014138101A1 (en) 2013-03-04 2014-09-12 Board Of Regents, The University Of Texas System Gene signature to predict homologous recombination (hr) deficient cancer
AU2014248007B2 (en) * 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
WO2015136017A1 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
CN105384695B (zh) * 2014-08-22 2019-12-20 四川海思科制药有限公司 嘧啶衍生物及其制备方法和在医药上的应用
CA2959072A1 (en) 2014-08-25 2016-03-03 Creatv Microtech, Inc. Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
US20160160294A1 (en) 2014-12-08 2016-06-09 Tesaro Methods and materials for predicting response to niraparib
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
SI3317281T1 (sl) 2015-07-02 2020-08-31 Acerta Pharma B.V. Trdne oblike in formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin -2-il)imidazo(1,5-a)pirazin-1-il)-n-(piridin-2-il)benzamida
CA3003422A1 (en) 2015-10-26 2017-05-04 Medivation Technologies Llc Treatment of small cell lung cancer with a parp inhibitor
EP3414692A4 (en) 2016-02-12 2020-07-29 Nantomics, LLC HIGH-RATE IDENTIFICATION OF PATIENT-SPECIFIC NEOEPITOPES AS THERAPEUTIC TARGETS FOR CANCER IMMUNOTHERAPIES
CN108697666A (zh) * 2016-02-29 2018-10-23 辛塔制药公司 用于治疗卵巢癌的组合疗法
EP3478286B1 (en) 2016-06-29 2024-01-03 Tesaro, Inc. Methods of treating ovarian cancer
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
CN106496187A (zh) 2016-09-14 2017-03-15 陕西科技大学 一种制备PARP抑制剂Niraparib的合成方法
CN106432055A (zh) 2016-09-17 2017-02-22 青岛辰达生物科技有限公司 一种尼拉帕布中间体4‑（哌啶‑3‑基）苯胺的制备方法
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
EP3606523A1 (en) 2017-03-27 2020-02-12 Tesaro, Inc. Niraparib formulations
MA48475A (fr) 2017-04-24 2020-03-04 Tesaro Inc Procédés de fabrication de niraparib
NZ759517A (en) 2017-04-27 2025-02-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
US20200129482A1 (en) 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer
BR112020006039A2 (pt) 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
KR20200105862A (ko) 2017-12-27 2020-09-09 테사로, 인코포레이티드 암을 치료하는 방법
TW202116316A (zh) 2019-07-15 2021-05-01 美商提薩羅有限公司 治療卵巢、輸卵管及腹膜癌之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015108986A1 (en) 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Oncology，Vol. 32, Issue 15，2014年
The LANCET Oncology，2014年，Vol. 15, Issue 8，p. 852-861

Also Published As

Publication number Publication date
IL263925A (en) 2019-01-31
US12383542B2 (en) 2025-08-12
CA3029671C (en) 2023-08-15
US20240058319A1 (en) 2024-02-22
WO2018005818A1 (en) 2018-01-04
IL263925B1 (en) 2023-08-01
NZ749413A (en) 2023-05-26
CN109640992A (zh) 2019-04-16
KR102510996B1 (ko) 2023-03-16
IL263925B2 (en) 2023-12-01
JP2019524690A (ja) 2019-09-05
EP4302835A2 (en) 2024-01-10
MX394062B (es) 2025-03-19
ES2969816T3 (es) 2024-05-22
CA3029671A1 (en) 2018-01-04
SMT202400105T1 (it) 2024-05-14
US20220175751A1 (en) 2022-06-09
MX2018016193A (es) 2019-06-10
JP2022031478A (ja) 2022-02-18
US20220175752A1 (en) 2022-06-09
AU2017290244B2 (en) 2023-03-02
KR20190029618A (ko) 2019-03-20
EP4302835A3 (en) 2024-03-20
SG11201811564QA (en) 2019-01-30
EP3478286A1 (en) 2019-05-08
DK3478286T3 (da) 2024-01-29
AU2017290244A1 (en) 2019-01-24
KR20230042136A (ko) 2023-03-27
SI3478286T1 (sl) 2024-03-29
US20220395493A1 (en) 2022-12-15
HRP20240136T1 (hr) 2024-04-12
EP3478286B1 (en) 2024-01-03
US20180311224A1 (en) 2018-11-01
PL3478286T3 (pl) 2024-04-22
LT3478286T (lt) 2024-04-25
PT3478286T (pt) 2024-01-31
BR112018077492A2 (pt) 2019-04-09
RS65180B1 (sr) 2024-03-29
EP3478286A4 (en) 2020-03-18
HUE064978T2 (hu) 2024-04-28
FI3478286T3 (fi) 2024-03-14

Similar Documents

Publication Publication Date Title
JP7083760B2 (ja) 卵巣癌の治療方法
JP7337805B2 (ja) がんを処置する方法
CN115867669A (zh) 监测kras突变的方法
US20210251998A1 (en) Systems and methods for treating cancer
JP2023517078A (ja) ツカチニブを用いてｈｅｒ２突然変異を有するがんを処置する方法
WO2021011609A1 (en) Methods of treating ovarian, fallopian tube and peritoneal cancer
HK40113232A (en) Methods of treating ovarian cancer
HK40098135A (en) Methods of treating ovarian cancer
BR122024025043A2 (pt) Uso de uma quantidade terapeuticamente eficaz de um inibidor de poli [adp-ribose] polimerase (parp), ou de um sal terapeuticamente aceitável do mesmo
HK40007084A (en) Methods of treating ovarian cancer
HK40007084B (en) Methods of treating ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220601

R150 Certificate of patent or registration of utility model

Ref document number: 7083760

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250